Filing Flows › Health Care › Hyperfine (HYPR)
Hyperfine (HYPR) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 6, 2026 · Hyperfine (HYPR) Q2 2026 earnings results →
Q2 2026 Revenue up 45% year over year to $3.9M · 238¢ of every $1 of revenue lost · operating margin -216.9%
Hyperfine made $3.9M in Q2 2026 (+45% Y/Y): Product $3.2M, Service $734K. Operating margin -216.9%, net loss $9.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $3.9M in Q2 2026, up 45% year over year and roughly flat from the previous quarter. Product was the largest line at 81% of revenue. Product added $1.0M year over year (up 49%), 86% of the total change.
Gross margin was 50.7%, up 1.5 points from Q2 2025. Operating costs exceeded revenue by $8.5M, an operating margin of -216.9%. Operating expenses fell 4% while revenue rose 45%. The quarter ended with a net loss of $9.3M, wider than the previous quarter's $8.6M loss.
Operating cash flow was −$7.3M. Non-cash charges added back $264K of depreciation and $903K of share-based compensation. Working capital and other items added $863K. Capital expenditures of $30K exceeded it, leaving free cash flow of −$7.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 6, 2026 | $3.9M | +45% | -216.9% | −$9.3M | −$7.3M |
| Q1 2026 | 10-Q | May 12, 2026 | $3.9M | +83% | -219.3% | −$8.6M | −$9.0M |
| Q4 2025 | 10-K | Mar 18, 2026 | $5.3M | +128% | -144.9% | −$5.9M | −$5.2M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $3.4M | -6% | -259.5% | −$11.0M | −$5.6M |
| Q2 2025 | 10-Q | Aug 13, 2025 | $2.7M | -26% | -355.9% | −$9.2M | −$7.9M |
| Q1 2025 | 10-Q | May 13, 2025 | $2.1M | -35% | -510.2% | −$9.4M | −$9.2M |
| Q4 2024 | 10-K | Mar 17, 2025 | $2.3M | -14% | -463.8% | −$10.4M | −$8.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About Hyperfine
We are an innovative health technology business with a mission to revolutionize patient care globally through accessible, affordable, clinically relevant artificial intelligence (“AI”)-powered portable ultra-low-field (“ULF”) magnetic resonance (“MR”) brain imaging. Our Swoop® Portable MR Imaging® System (“Swoop® system”) produces high-quality images at a significantly lower magnetic field strength than conventional magnetic resonance imaging (“MRI”) scanners. Our Swoop® system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated patient-friendly experience, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop® system is a portable, ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical.
In its own words, from its 10-K, filed Mar 18, 2026.
Hyperfine against its Electromedical & Electrotherapeutic Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +45% against the peers' median +14%. Operating margin: -216.9% against the peers' median 6.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| HYPR Hyperfine | Q2 2026 | $3.9M | +45% | -216.9% |
| MDT Medtronic | Q1 FY27 | $9.8B | +14% | 18.1% |
| ITGR Integer Holdings | Q3 2026 | $450M | -4% | 6.3% |
| LIVN LivaNova | Q3 2026 | $393M | +10% | 7.2% |
| CNMD Conmed | Q3 2026 | $336M | -0.7% | 11.1% |
| TMDX TransMedics Group | Q3 2026 | $203M | +41% | 13.9% |
| AXGN Axogen | Q3 2026 | $75.8M | +26% | 1.3% |
| OM Outset Medical | Q3 2026 | $33.6M | +14% | -36.5% |
| CBLL Ceribell | Q3 2026 | $29.3M | +30% | -70.0% |
Source: Hyperfine 10-Q on SEC EDGAR · CIK 1833769 · Electromedical & Electrotherapeutic Apparatus
13F: who owns HYPR and who is buying
More on HYPR
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results